These mechanisms appear to be relevant in vivo in the context of combinatorial co‐targeting regimens, as triple therapy targeting adaptive induction of CLU plus Wee1 optimally inhibited tumor growth compared to mono or double therapy regimens. The gene discussed is WEE1; the disease is neoplasm.